IntegenX Inc., a privately held company that is a leader in the emerging field of rapid human DNA identification, today announced that it has acquired SV Corp, a wholly owned subsidiary of GE Healthcare Bio-Sciences. IntegenX will leverage SV Corp's products and intellectual property assets to expand its consumables offering and to accelerate the commercialization of its RapidHIT™ 200 Human DNA Identification System. GE Healthcare Bio-Sciences is a subsidiary of GE Healthcare. Financial terms of the agreement were not disclosed.
“This acquisition marks an important milestone in IntegenX's introduction of our first commercially available system for rapid human DNA identification”
"This acquisition marks an important milestone in IntegenX's introduction of our first commercially available system for rapid human DNA identification," said Dr. Stevan Jovanovich, Chief Executive Officer of IntegenX. "The SV Corp acquisition brings to IntegenX proprietary products and a proven and protected IP estate containing key technical know-how in capillary electrophoresis, separation, sample preparation, and separation matrix."
As a result of the acquisition, IntegenX will take over supplying capillaries and matrix to the more than 100 existing users of GE's MegaBACE™ sequencers. These products will also be integrated into the RapidHIT system.
Set to commercially launch later this year, the IntegenX RapidHIT 200 is a self-contained Human Identification (HID) system that automates and accelerates the process of producing standardized DNA profiles from mouth swabs and other human samples in less than 90 minutes. Numerous local, state, national, and international law enforcement and security agencies use DNA-based human identification to make informed identification decisions regarding the arrest, detention, or release of suspects, as well as to analyze crime scene evidence. The RapidHIT system will allow rapid DNA analysis at the point of collection — such as on arrest or detention — a new approach in the usage of DNA profiles as an actionable biometric similar to fingerprints.
Neoantigen DNA vaccines improve survival and immunity in triple-negative breast cancer patients